세계의 스텐트 시장 규모, 점유율, 성장 분석 : 제품 유형별, 재료별, 최종사용자별, 산업 예측(2022-2028년)
Global Stents Market Size, Share, Growth Analysis, By Product Type(Coronary Stents, Peripheral Stents), By Material(Metallic Biomaterial, Polymer Biomaterial), By End User(Hospital, Ambulatory Surgical Centers) - Industry Forecast 2022-2028
세계의 스텐트 시장 규모는 2021년에 88억 달러를 기록했으며, 2022년 93억 달러에서 2030년까지 121억 달러에 달하며, 2023-2030년의 예측 기간 중 3.3%의 CAGR로 성장할 것으로 예측되고 있습니다.
스텐트 시장은 심혈관질환의 유병률 상승·고령자 인구의 확대를 배경으로 예측 기간 중 큰 성장을 달성할 전망입니다. 또한 기술 진보와 저침습수술의 수요 증가가 시장 성장을 한층 더 촉진할 것으로 기대됩니다. 그러나 스텐트 시술 관련 엄격한 규제나 고액의 비용이 시장 성장을 다소 방해할 가능성이 있습니다.
세계의 스텐트 시장에 대해 조사분석했으며, 시장 동향, 경쟁 구도, 부문별·지역별 시장 분석, 주요 기업의 개요 등의 정보를 제공하고 있습니다.
Global Stents Market size was valued at USD 8.8 billion in 2021 and is poised to grow from USD 9.3 billion in 2022 to USD 12.1 billion by 2030, growing at a CAGR of 3.3% in the forecast period (2023-2030).
The stents market is expected to witness significant growth over the forecast period, driven by increasing prevalence of cardiovascular diseases and a growing geriatric population. Stents are small, expandable tubes used to treat narrowed or weakened arteries in the body. The market is highly competitive, with major players focusing on product innovation and strategic partnerships. Technological advancements and increasing demand for minimally invasive procedures are expected to further propel market growth. However, strict regulations and high costs associated with stent procedures may hinder market growth to some extent.
Top-down and bottom-up approaches were used to estimate and validate the size of Stents market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Segments covered in this report
The global stents market is segmented based on the product type, material, end user, and region. Based on the product, the market is segmented into coronary stents, peripheral stents, and stent related implant. Based on the material, the market is segmented into metallic biomaterial, polymer biomaterial, and natural biomaterial. Based on the end user, the market is segmented into hospital, ambulatory surgical centers, and others. Based on the region, the market is categorized into North America, Europe, Asia-Pacific, South America, and MEA.
The stent market is expected to experience growth in the near future due to the increasing incidence of cardiovascular diseases. The rising prevalence of cardiovascular ailments across the globe is anticipated to drive demand for percutaneous coronary intervention and peripheral vascular procedures. According to the World Health Organization (WHO), cardiovascular diseases (CVDs) cause approximately 17.9 million deaths annually, accounting for almost one-third of all global fatalities. As the number of people affected by cardiovascular diseases continues to rise, the demand for stents, percutaneous coronary intervention, and peripheral vascular operations is also expected to increase.
The expansion of the stent market is hindered by stringent regulatory requirements. Several agencies and governmental bodies have established guidelines and regulations for the safe and effective use of stents. To obtain approval for stents, the FDA conducts a comprehensive analysis of the literature and preclinical studies on animals. The approval process for medical devices, including coronary stents, is resource-intensive in terms of both time and money, as they are classified as class III devices by the USFDA. Due to the potential risks associated with stent devices, strict controls have been implemented. The FDA closely monitors their usage in the United States. Additionally, stents are classified as class II and III medical devices, which poses moderate to high risks, and they must adhere to rigorous regulatory compliance, limiting the overall market demand.
Continuous product innovations and improvements have been instrumental in driving the growth of the stents market. Manufacturers have focused primarily on making slight modifications, such as reducing the thickness of stent struts, improving stent deliverability in tortuous veins, and introducing stents with longer lengths or smaller diameters. The introduction of the Xience Sierra stent in 2018, which received FDA approval in the United States, is an example of one of the latest breakthroughs in stent technology. These enhancements, including increased flexibility, smaller profiles, smaller diameters, and longer lengths, aim to address important percutaneous coronary procedures (PCI) and improve the patient experience while reducing procedural difficulties, ultimately driving market growth.